You are here

Study Of Lybrel In Relation To Venous Thromboembolism

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Venous Thrombosis, Pulmonary Embolism, Intracranial Sinus Thrombosis
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
15-49 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- New users of the study drugs (i.e., Lybrel and the comparison OCs)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- No specific exclusion criteria for the base study cohort.

NCT01297348
Pfizer
Completed
Study Of Lybrel In Relation To Venous Thromboembolism

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
NCT02743871
All Genders
18+
Years
Multiple Sites
Venous Thromboembolism
NCT02464969
All Genders
0+
Years
Multiple Sites
Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Study Of Lybrel In Relation To Venous Thromboembolism
Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl estradiol (90 ?g/20 ?g). Lybrel is taken on a continuous basis without a placebo or pill-free interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective of this database case-control study is to estimate the risk of idiopathic VTE (deep vein thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol 20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing 20?g of ethinyl estradiol.
The base population consists of all currently available data on current users (15-49 years old) of Lybrel and other oral contraceptives (OC) containing 20 µg ethinyl estradiol in the PharMetrics/IMS and MarketScan databases. From among the base population, the databases are then searched for any diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) [referred to collectively as venous thromboembolism or VTE] that occurred after receipt of Lybrel or other oral contraceptives containing 20 µg ethinyl estradiol. The intent is to include newly diagnosed cases of VTE.
Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
The base population for each year of the study will comprise all 15 - 49 year old women who have any recorded prescriptions for either continuous use ethinyl estradiol 20ug/levonorgestrel 90ug or a cyclic oral contraceptive that contains 20 µg ethinyl estradiol. The women are identified from PharMetrics and MarketScan databases. Additionally, women are enrolled if the index prescription is a new one; this is defined as a prescription dispensed following a 4-month window in which no combined hormonal contraception prescriptions were filled.
  • Venous Thrombosis
  • Pulmonary Embolism
  • Sinus Thrombosis, Intracranial
  • Drug: 90ug levonorgestrel / 20 ug ethinyl estradiol
    This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
    Other Name: Lybrel
  • Drug: Oral Contraceptives containing 20 ug of ethinyl estradiol
    This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
    Other Name: Lessina, Aviane, Junel 1/20, Junel FE 1/20, Levlite, Lutera, Alesse, Loestrin FE 1/20, Loestrin 1/20, Microgestin 1/20, Microgestin FE 1/20
  • Lybrel®
    Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
    Intervention: Drug: 90ug levonorgestrel / 20 ug ethinyl estradiol
  • Other OCs containing 20?g of ethinyl estradiol
    Current users of oral contraceptives containing 20?g of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
    Intervention: Drug: Oral Contraceptives containing 20 ug of ethinyl estradiol
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
598682
April 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • New users of the study drugs (i.e., Lybrel and the comparison OCs)

Exclusion Criteria:

  • No specific exclusion criteria for the base study cohort.
Sexes Eligible for Study: Female
15 Years to 49 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01297348
0858A2-4406
B3121004
No
Not Provided
Not Provided
Pfizer
Pfizer
Boston Collaborative Drug Surveillance Program
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now